Momordica charantia extracts ameliorate insulin resistance by regulating the expression of SOCS-3 and JNK in type 2 diabetes mellitus rats

References

• Adeghate E, Schattner P, Dunn E. 2006. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 1084:1–29.
   PubMed Web of Science ®Google Scholar
• Chao CY, Sung PJ, Wang WH, Kuo YH. 2014. Anti-inflammatory effect of Momordica charantia in sepsis mice. Molecules. 19:12777–12788.
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, George S, Milinganyo M, Tripathi YB. 2004. Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats. Phytother Res. 18:954–956.
   PubMed Web of Science ®Google Scholar
• Chen Q, Chan LL, Li ET. 2003. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizers glucose tolerance in rats fed a high fat diet. J Nutr. 133:1088–1093.
   PubMed Web of Science ®Google Scholar
• Choi JJ, Park MY, Lee HJ, Yoon DY, Lim Y, Hyun JW, Zouboulis CC, Jin M. 2012. TNF-α increases lipogenesis via JNK and PI3K/Akt pathways in SZ95 human sebocytes. J Dermatol Sci. 65:179–188.
   PubMed Web of Science ®Google Scholar
• Chun CS, Cheng HL, Wei LL, Wu JB. 2009. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol. 123:82–90.
   PubMed Web of Science ®Google Scholar
• Chun CS, Min TS, Cheng HL, Jin BW. 2014. Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytother Res. 28:363–371.
   PubMed Web of Science ®Google Scholar
• Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 11:98–107.
   PubMed Web of Science ®Google Scholar
• Efird JT, Choi YM, Davies SW, Mehra S, Anderson EJ, Katunga LA. 2014. Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes. Int J Environ Res Public Health. 11:2328–2345.
   PubMed Web of Science ®Google Scholar
• Fujino H, Itoda S, Sako S, Matsuo K, Sakamoto E, Yokoyama T. 2013. Reliability of HOMA-IR for evaluation of insulin resistance during perioperative period. Masui. 62:140–146.
   PubMedGoogle Scholar
• Galic S, Sachithanandan N, Kay TW, Steinberg GR. 2014. Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity. Biochem J. 461:177–188.
   PubMed Web of Science ®Google Scholar
• Habicht SD, Ludwig C, Yang RY, Krawinkel MB. 2014. Momordica charantia and type 2 diabetes: from in vitro to human studies. Curr Diabetes Rev. 10:48–60.
   PubMedGoogle Scholar
• Hashimoto R, Sakai K, Matsumoto H, Iwashita M. 2010. Tumor necrosis factor-alpha (TNF-alpha) inhibits insulin-like growth factor-I (IGF-I) activities in human trophoblast cell cultures through IGF-I/insulin hybrid receptors. Endocr J. 57:193–200.
   PubMed Web of Science ®Google Scholar
• Hazarika R, Parida P, Neog B, Yadav RNS. 2012. Binding Energy calculation of GSK-3 protein of Human against some anti-diabetic compounds of Momordica charantia linn (Bitter melon). Bioinformation. 8:251–254.
   PubMedGoogle Scholar
• Kalupahana NS, Moustaid MN, Claycombe KJ. 2012. Immunity as a link between obesity and insulin resistance. Mol Aspects Med. 33:26–34.
   PubMed Web of Science ®Google Scholar
• Koren S, Fantus G. 2007. Inhibition of the protein tyrosine phosphatase PTP-1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 21:621–640.
   PubMed Web of Science ®Google Scholar
• Kumar R, Balaji S, Uma TS, Sehgal PK. 2009. Fruit extracts of Momordica charantia potentiate glucose uptake and up-regulate Glut-4, PPAR gamma and PI3K. J Ethnopharmacol. 126:533–537.
   PubMed Web of Science ®Google Scholar
• Kwon H, Pessin JE. 2013. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 4:71.
   PubMedGoogle Scholar
• Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. 2009. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr. 102:1703–1708.
   PubMed Web of Science ®Google Scholar
• Lee BC, Lee J. 2014. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 1842:446–462.
   PubMed Web of Science ®Google Scholar
• Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I. 2001. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol. 47:340–344.
   PubMed Web of Science ®Google Scholar
• Ojuka EO, Jones TE, Nolte LA, Chen M, Wamhoff BR, Sturek M, Holloszy JO. 2002. Regulation of GLUT4 biogenesis in muscle: evidence for involvement of AMPK and Ca2+. Am J Physiol Endocrinol Metab. 282:1008–1013.
   PubMed Web of Science ®Google Scholar
• Roach PJ, Depaoli RA, Hurley TD, Tagliabracci VS. 2012. Glycogen and its metabolism: some new developments and old themes. Biochem J. 441:763–787.
   PubMed Web of Science ®Google Scholar
• Sharfi H, Eldar-Finkelman H. 2008. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab. 294:307–315.
   PubMed Web of Science ®Google Scholar
• Sharma BR, Kim HJ, Rhyu DY. 2015. Caulerpa lentillifera extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes. J Transl Med. 13:62.
   PubMed Web of Science ®Google Scholar
• Shi H, Tzameli I, Bjorbaek C, Flier JS. 2004. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem. 279:34733–34740.
   PubMed Web of Science ®Google Scholar
• Soo JY, Jung MC, Se EP, Eun JR, Won YL, Ki WO, Sung WP, Cheol YP. 2015. Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats. J Nutr Biochem. 26:234–240.
   PubMed Web of Science ®Google Scholar
• Spasov AA, Samokhina MP, Kheyfets IA, Dugina JL, Martyushev Poklad AV, Sergeeva SA, Epstein OI. 2007. Study of antidiabetic activity of a new ultralow-dose antibody preparation on the model of streptozotocin diabetes in rats. Bull Exp Biol Med. 144:46–48.
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Kanno T, Nishizaki T. 2014. PI3 kinase directly phosphorylates Akt1/2 at Ser473/474 in the insulin signal transduction pathway. J Endocrinol. 220:49–59.
   PubMed Web of Science ®Google Scholar
• Yoshihiro I, Ryoichi B, Shigeru H, Ozawa Y, Arima H, Oiso Y. 2012. TNFα increases hypothalamic PTP-1B activity via the NF κB pathway in rat hypothalamic organotypic cultures. Regul Pept. 174:58–64.
   PubMedGoogle Scholar
• White MF. 2002. Irs proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 3:413–422.
   Web of Science ®Google Scholar
• Wormald S, Hilton DJ. 2004. Inhibitors of cytokine signal transduction. J Biol Chem. 279:821–824.
   PubMed Web of Science ®Google Scholar
• Yin J, Zhang H, Ye J. 2008. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 8:99–111.
   PubMedGoogle Scholar